Skip to main content

Arcturus Therapeutics Holdings Inc 10-Q for FY2026 Q3

Arcturus Therapeutics Holdings Inc. (ARCT)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Arcturus Therapeutics Holdings Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Arcturus Therapeutics Holdings Inc. recognized approximately $16.8 million of revenue after terminating its CSL Seqirus collaboration, regaining KOSTAIVE and other vaccine programs. Nine-month revenue fell $51.5 million, while cash and cash equivalents were $184.8 million at September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$18.3M
up 6.7% from $17.15M a year earlier
Net loss
$7.41M
compared with a net loss of $13.45M a year earlier
Diluted EPS
-$0.26
compared with -$0.49 a year earlier